NCT00661583View on ClinicalTrials.gov

Use of Ranibizumab With Mitomycin C During Trabeculectomy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

September 30, 2014

Study Completion Date

September 30, 2014

Conditions
Glaucoma
Interventions
DRUG

Ranibizumab

0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed

DRUG

Ranibizumab and MMC

Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy

DRUG

MMC

MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.

Trial Locations (1)

80045

Rocky Mountain Lions Eye Institute, Aurora

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

University of Colorado, Denver

OTHER